| General Information of Drug-Metabolizing Enzyme (DME ID: DME1319) |
| DME Name |
Beta-lactamase (blaB), Bacteroides intestinalis
|
DME Info
|
| UniProt ID |
|
| EC Number |
EC: 3.5.2.6 (Click to Show/Hide the Complete EC Tree)
Hydrolases
Carbon-nitrogen hydrolase
Cyclic amide hydrolase
EC: 3.5.2.6
|
| Lineage |
Species: Bacteroides intestinalis (Click to Show/Hide the Complete Species Lineage)
Kingdom: Bacteria
Phylum: Bacteroidetes
Class: Bacteroidia
Order: Bacteroidales
Family: Bacteroidaceae
Genus: Bacteroides
Species: Bacteroides intestinalis
|
| Interactome |
|
| Disease Specific Interactions between Host Protein and DME (HOSPPI) |
| Drug co-metabolism |
| Cometabolized drug: Amoxicillin |
Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI
|
| Mephenytoin 4-hydroxylase (CYP2C19) |
Click to Show/Hide the Cometabolization Info |
| DME ID |
DME0021
DME Info
|
| Uniprot ID |
|
| Interaction Name |
CYP2C19-blaB interaction |
[1], [2] |
| Description |
The interaction, between human Mephenytoin 4-hydroxylase and Beta-lactamase from Bacteroides intestinalis which collectively metabolize the drug Amoxicillin, is reported to affect the efficacy, safety or bioavailability of this drug via interfering with it metabolism. |
|
|
|
|
|
|
| References |
| 1 |
Prevalence of antimicrobial resistance genes in Bacteroides spp. and Prevotella spp. Dutch clinical isolates. Clin Microbiol Infect. 2019 Sep;25(9):1156.e9-1156.e13.
|
| 2 |
High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
|
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.
